Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, discusses acute myeloid leukemia (AML) in the context of the COVID-19 pandemic. The prevalence of healthcare disparities across the nation and globally makes AML treatment particularly challenging during the pandemic as many patients are immunocompromised. Because therapeutic treatment is time sensitive, AML patients cannot wait until COVID-19 is contained to seek medical care for testing, therapies, and procedures in the clinic.
- ? In case you missed it! During the 2nd NCRI AML Academy, Nigel Russell shared updates from AML18 and AML19 trials… https://t.co/tTV5uIArXf
- RT @MDSAlliance: Struggling to know when you need to see the doctor? If you are experiencing any #MDS symptoms, it is important to speak t…
- During #TCTM21, the @AML_Hub spoke to James Yu, @AdventHealthCFL. We asked, How does the mutation profile differ be… https://t.co/GVxsgk2CLv
- Clinical evaluation of Ab-based therapeutics in #AML review ?@Daver_Leukemia #leusm #leukemia https://t.co/C4a6GzhYso
- ? CONGRESS | Listen to Naval Daver when he spoke to the @AML_Hub during #CART21. We asked, How can we improve eff… https://t.co/kRc6G7ttxu
- ? Does CPX-351 + venetoclax have potential in treating patients with R/R or newly diagnosed AML?… https://t.co/9yJ6hywqaQ
- During #TCTM21, the @AML_Hub spoke to James Yu, @AdventHealthCFL. We asked, How do methylation regulatory gene muta… https://t.co/MjilTqWJ5Q
- ? CPX-351 demonstrates increased overall survival compared to standard 7+3 in patients with a high risk of mortalit… https://t.co/XoxmSjKfOH
- In this very high-risk population of TP53m MDS and #AML patients, eprenetapopt combined with AZA was safe and show… https://t.co/JByjBJMokg
- RT @rarediseaseday: 5? days to go! 5? ways to get involved! Tell your story? Share the video ?? Submit your event ? Download the materials…
- ?? Phase I clinical trial demonstrates positive safety and efficacy outcomes with JSP191 conditioning in elderly pa… https://t.co/yyZMA4s2Ol
- Interested in the practice-changing abstracts in #AML from #ASH20? Here’s the list from our steering committee??… https://t.co/Z4EoujRnT7
- RT @sanamloghavi: Excited to share our new paper just out in British journal of Haematology #hemapth #leusm #flowEdu #tweetorial ?1/ #PubAl…
- During #TCTM21, the @AML_Hub was pleased to speak to @BrendaMarie99, @fredhutch. We asked, How safe and efficacious… https://t.co/fleZaovRtt
- RT @drsangeetmd: Clonal evolution of FLT3-ITD mutated AML with midostaurin @BloodJournal | FLT3 bypass or selects clones under selective pr…
- Have you read this @AML_Hub article? ?? Can MRD-directed therapy improve outcomes for patients with persistent or… https://t.co/xQcE3tVhDd
- In case you missed it ? The @AML_Hub will be exploring the progress being made in frontline chemotherapy options fo… https://t.co/DMCzYtg2wO
- RT @WCMLeukemia: Patients with acute myeloid #leukemia (#AML) who have gone into remission following initial #chemotherapy remain in remiss…
- RT @MyLeukemiaTeam: REMINDER: Everyone is on their own journey. Meet thousands of others living with #leukemia: https://t.co/zqk3CJXpSB htt…
- RT @mattovdarlo: Finally cancer free ?
- RT @AnimatedPatient: What is #AML and what causes it? In this You And AML video, Dr David Steensma describes #acutemyeloidleukemia, a bloo…
- RT @MDSAlliance: WE NEED YOUR HELP! By retweeting this post, you can help spread awareness so that more people are familiar with the sympt…
- RT @MDAndersonNews: "The future of treatment for patients with AML is moving away from one-size-fits-all to a very individualized approach,…
- Approximately 3/4 of patients with relapsed and/or refractory multiple #myeloma responded to treatment with teclist… https://t.co/nMtle99suO
- “I was aware at an early age that not everyone has access to the same health care, resources, opportunities and edu… https://t.co/awwn4dU4eJ
- Your doctor may suggest any of the following treatments for refractory #AML: chemotherapy, stem cell transplant, ta… https://t.co/UukB9ah1at
- Presented by @AliTaherMD at #ASH20: Treatment with luspatercept was associated with sustained reductions in red blo… https://t.co/vdheygM2aT
- In a report published in @BloodJournal, researchers evaluated a new strategy to maximize graft-versus-leukemia effe… https://t.co/MCdwiVIpOh
- Cracking the Code of Ethics: Physicians who responded to @Medscape survey on ethical dilemmas had mixed opinions on… https://t.co/raoJgYz5Vp
- According to data presented at #ASH20, gene editing may provide sufficient therapeutic benefit for patients with… https://t.co/krfMMKJ7HW
- The @NIH announced that it is pausing enrollment of patients with severe COVID-19 in 3 trials that are evaluating a… https://t.co/JPvCeXjnav
- You Make the Call: How would you treat this patient with aggressive systemic #mastocytosis? Email us at ashclinical… https://t.co/lwMICdtSu3
- RT @StanfordDeptMed: .@ASHClinicalNews spotlights #StanDOM's @TamaraDunnMD & her musical talent that brings smiles to patients' faces & is…
- A pediatric disease risk index reported in @BloodJournal was capable of stratifying children with acute myeloid… https://t.co/QiZdVif6Gp
- RT @WorldCCADay: Today is World Cholangiocarcinoma (CCA) Day! Let's come together and shine a light on #cholangiocarcinoma. We look forward…
- Refractory #AML occurs when, even after treatment, e.g., 2 cycles of chemotherapy, leukemia cells are still present… https://t.co/kpDbkjThc1
- COVID-19 and Clots: Among patients hospitalized with #COVID19, those who received aggressive high-dose therapeutic… https://t.co/xHv0X4O66P
- “If you are unhappy and burned out, you definitely want to be careful about making any decisions where you are just… https://t.co/yAiKZjtnxA
- The Future of Graft-Versus-Host Disease: @StevenPavletic and Kirk Schultz, MD, report on the progress and challenge… https://t.co/tZqrUutW0Q
- RT @Roscodaddy: @KNOW_AML Some good news Nathaniel has been offered to be treated on venetoclax and azacitidine 3 cycles at GOSH to see if…
- “May I Have Your Attention, Please?” A @DrFirst survey found that 73% of men and 39% of women confess to multitaski… https://t.co/aGIZEFXVbY
- RT @MDSAlliance: This National Cancer Prevention Month we want to ensure that everyone is aware of the most common signs and symptoms of MD…
- RT @SireniaDaptari: @KNOW_AML Getting yearly blood checkups is a good idea too. That's how they found my MDS (which turned into AML). They…
- RT @BTMPublicPolicy: Thank you, @KNOW_AML for raising awareness about this blood cancer. #NationalCancerPreventionMonth ?? https://t.co/Y8o…
- Presented by Ruben Rhoades, MD, at #ASH20: Inherited thrombophilias are associated with an increased risk of initia… https://t.co/UGx5QWTgc4
- Congratulations to our Koichi Takahashi, M.D., Ph.D., @DrKTakahashi, of @MDAndersonNews #Leukemia, for being select… https://t.co/yxuMvaSzrQ
- RT @MDAndersonNews: Our cancer patients depend on blood and platelet donations, and right now our need for type O blood donations is especi…
- RT @doctorpemm: Wishing each of you a happy, healthy week filled w/innovation, prosperity & discovery on behalf of our patients with cancer…
- RT @MissionBio: Join us on Nov 9 to hear from two experts in the field of hematology, Dr. Michael Andreeff @MDAndersonNews and Dr. Peter Va…
- RT @gotoPER: Join our #ASH20 FSS Individualizing MF and PV Treatment program with Program Chair Srdan Verstovsek, MD, to keep up to date wi…
- RT @HelixBioPharma: Congrats! @MDAndersonNews Keep up the good work! Thanks to CAR T cell therapy, patients with lymphoma and leukemia have…
- RT @practiceupdate: Leukemic Evolution of Polycythemia Vera and Essential Thrombocythemia. Commentary by Srdan Verstovsek MD @MDAndersonNe…
- RT @VJHemOnc: Did you miss out on the #AML Sessions - venetoclax-based regimens? You can still watch @Daver_Leukemia, Courtney DiNardo, Ma…
- RT @VJHemOnc: ?Don't forget to check out our #AML Sessions w/ @Daver_Leukemia, Courtney DiNardo, Marina Konopleva & Andrew Wei! Now availa…
- RT @power4patients: Which #AML mutations can affect prognosis and treatment? @Daver_Leukemia of @LeukemiaMDA explains. #leusm #FLT3 #IDH1…
- RT @MDAndersonNews: “With immunotherapy, we are trying to harness or reinvigorate the immune system so that it recognizes and attacks the c…
- RT @achlcme: YOUR path, YOUR rules! This enhanced digital algorithm combines stepwise practical guidance with evidence-based education on t…
- RT @yazan_14: Honored to be presenting my first ASH oral presentation!!!. special thanks to @jaltmanmd & @bpromd for their mentorship. @McG…
- RT @ASCO_pubs: Mutant IDH1 inhibitor ivosidenib plus azacitadine was well tolerated in patients with IDH1-mutated newly-diagnosed acute mye…
- RT @doctorpemm: ???Our group’s new paper led by Dr Montalban-Bravo & @garciamanero ?? Clinical Outcomes and Influence of Mutation Clonal Do…
